The company intends to invest a lower double-digit million euro sum in its production facility in Memphis, USA.

Due to the continuous strong demand for disinfectants, Lanxess is planning to expand its production capacity for Oxone monopersulfate by around 50 percent. The company intends to invest a lower double-digit million euro sum in its production facility in Memphis, USA.
Lanxess uses Oxone monopersulfate as the main active ingredient in many of its Virkon and Rely+On disinfection products. Demand for these products has increased significantly in recent months due to, amongst others, the outbreak of African swine fever as well as the corona pandemic. The company also sells Oxone as a powerful oxidizing agent for numerous other applications. The capacity expansion is expected to be completed in the second half of 2022.
"Disinfection products are important growth drivers in our highly profitable Consumer Protection segment. We expect a sustainable high level of demand even after the corona pandemic," said Matthias Zachert, Chairman of the Lanxess Board of Management.
Michael Schäfer, head of Lanxess' Material Protection Products business unit, added: "We are also seeing a growing demand for Oxone in the water treatment sector as well as from the electronics and paper industries. We want to meet this demand by expanding our production capacity."
END